



## Announcement Summary

---

**Entity name**

MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED

**Announcement Type**

New announcement

**Date of this announcement**

Monday December 14, 2020

**The Proposed issue is:**

- An offer of securities under a securities purchase plan
- A placement or other type of issue

**Total number of +securities proposed to be issued for an offer of securities under a securities purchase plan**

<b>ASX +security code</b>	<b>+Security description</b>	<b>Maximum Number of +securities to be issued</b>
MVP	ORDINARY FULLY PAID	769,230

**+Record date**

Friday December 11, 2020

**Offer closing date**

Monday January 18, 2021

**+Issue date**

Wednesday January 27, 2021

**Total number of +securities proposed to be issued for a placement or other type of issue**

<b>ASX +security code</b>	<b>+Security description</b>	<b>Maximum Number of +securities to be issued</b>
MVP	ORDINARY FULLY PAID	3,846,154

**Proposed +issue date**

Friday December 18, 2020

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

---

**1.1 Name of +Entity**

MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

**1.2 Registered Number Type**

ABN

**Registration Number**

14106340667

**1.3 ASX issuer code**

MVP

**1.4 The announcement is**

New announcement

**1.5 Date of this announcement**

Monday December 14, 2020

**1.6 The Proposed issue is:**

An offer of +securities under a +securities purchase plan

A placement or other type of issue



Part 4 - Details of proposed offer under securities purchase plan

---

Part 4A - Conditions

---

**4A.1 - Are any of the following approvals required for the offer of +securities under the +securities purchase plan issue to be unconditional?**

- +Security holder approval
- Court approval
- Lodgement of court order with +ASIC
- ACCC approval
- FIRB approval
- Another approval/condition external to the entity

No

Part 4B - Offer details

---

**Class or classes of +securities that will participate in the proposed issue and class or classes of +securities proposed to be issued**

**ASX +security code and description**

MVP : ORDINARY FULLY PAID

**Will the proposed issue of this +security include an offer of attaching +securities?**

No

Details of +securities proposed to be issued

---

**ASX +security code and description**

MVP : ORDINARY FULLY PAID

**Maximum total number of those +securities that could be issued if all offers under the +securities purchase plan are accepted**

769,230

**Will the offer be conditional on applications for a minimum number of +securities being received or a minimum amount being raised (i.e. a minimum subscription condition)?**

No

**Will the offer be conditional on applications for a maximum number of +securities being received or a maximum amount being raised (i.e. a maximum subscription condition)?**

No



**Will individual security holders be required to accept the offer for a minimum number or value of +securities (i.e. a minimum acceptance condition)?**

Yes

**Is the minimum acceptance unit based or dollar based?**

Dollar based (\$)

**Please enter the minimum acceptance value**

\$ 650

**Will individual security holders be limited to accepting the offer for a maximum number or value of +securities (i.e. a maximum acceptance condition)?**

Yes

**Is the maximum acceptance unit based or dollar based?**

Dollar based (\$)

**Please enter the maximum acceptance value**

\$ 30,000

**Describe all the applicable parcels available for this offer in number of securities or dollar value**

Eligible shareholders may apply for a parcel of Shares with a dollar value of  
\$650 (100 shares); or  
\$1,300 (200 shares); or  
\$2,600 (400 shares); or  
\$3,900 (600 shares); or  
\$7,800 (1200 shares); or  
\$15,600 (2,400 shares); or  
\$23,400 (3,600 shares); or  
\$30,000 (4,615 shares)

**Offer price details**

**Has the offer price been determined?**

Yes

**In what currency will the offer be made?**

AUD - Australian Dollar

**What is the offer price per +security?**

AUD 6.50000

**Oversubscription & Scale back details**

**Will a scale back be applied if the offer is over-subscribed?**

Yes

**Describe the scale back arrangements**

The SPP will initially be capped at \$5m. However, the Board reserves the right in its absolute discretion to accept applications from eligible shareholders in excess of \$5m or to scale back applications (on a pro rata basis) if necessary. In the event of a scale back, eligible shareholders may not receive the full number of shares applied for under the SPP and the difference in any application monies will be refunded to them (without interest) following the issue of Shares under the SPP.



**Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?**

Yes

#### Part 4C - Timetable

---

**4C.1 Date of announcement of +security purchase plan**

Monday December 14, 2020

**4C.2 +Record date**

Friday December 11, 2020

**4C.3 Date on which offer documents will be made available to investors**

Friday December 18, 2020

**4C.4 Offer open date**

Friday December 18, 2020

**4C.5 Offer closing date**

Monday January 18, 2021

**4C.6 Announcement of results**

Thursday January 21, 2021

**4C.7 +Issue date**

Wednesday January 27, 2021

#### Part 4D - Listing Rule requirements

---

**4D.1 Does the offer under the +securities purchase plan meet all of the requirements of listing rule 7.2 exception 5 or do you have a waiver from those requirements?**

Yes

#### Part 4E - Fees and expenses

---

**4E.1 Will there be a lead manager or broker to the proposed offer?**

No

**4E.2 Is the proposed offer to be underwritten?**

No



**4E.3 Will brokers who lodge acceptances or renunciations on behalf of eligible +security holders be paid a handling fee or commission?**

No

**4E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed offer**

Fees and costs incurred by MVP in connection with the SPP include share registry fees, settlement fees and legal fees

Part 4F - Further Information

---

**4F.01 The purpose(s) for which the entity intends to use the cash raised by the proposed issue**

To principally fund the acceleration of Pentrox EU's commercial expansion through operational investments in the EU and Australia and completion of clinical studies. Refer to slide 14 of the investor presentation released on 14 Dec 2020.

**4F.1 Will the entity be changing its dividend/distribution policy if the proposed offer is successful?**

No

**4F.2 Countries in which the entity has +security holders who will not be eligible to accept the proposed offer**

All countries other than Australia and New Zealand

**4F.3 URL on the entity's website where investors can download information about the proposed offer**

<https://medicaldev.com/investors-media/>

**4F.4 Any other information the entity wishes to provide about the proposed offer**

No



Part 7 - Details of proposed placement or other issue

---

Part 7A - Conditions

---

**7A.1 - Are any of the following approvals required for the placement or other type of issue?**

- +Security holder approval
- Court approval
- Lodgement of court order with +ASIC
- ACCC approval
- FIRB approval
- Another approval/condition external to the entity

No

Part 7B - Issue details

---

**Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)?**

Existing class

**Will the proposed issue of this +security include an offer of attaching +securities?**

No

Details of +securities proposed to be issued

---

**ASX +security code and description**

MVP : ORDINARY FULLY PAID

**Number of +securities proposed to be issued**

3,846,154

**Offer price details**

**Are the +securities proposed to be issued being issued for a cash consideration?**

Yes

**In what currency is the cash consideration being paid?**

AUD - Australian Dollar

**What is the issue price per +security?**

AUD 6.50000

**Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?**

Yes



Part 7C - Timetable

---

**7C.1 Proposed +issue date**

Friday December 18, 2020

Part 7D - Listing Rule requirements

---

**7D.1 Has the entity obtained, or is it obtaining, +security holder approval for the entire issue under listing rule 7.1?**

No

**7D.1b Are any of the +securities proposed to be issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?**

Yes

**7D.1b ( i ) How many +securities are proposed to be issued without security holder approval using the entity's 15% placement capacity under listing rule 7.1?**

3,846,154

**7D.1c Are any of the +securities proposed to be issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)?**

No

**7D.2 Is a party referred to in listing rule 10.11 participating in the proposed issue?**

Yes

**7D.3 Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules?**

No

**7D.4 Will any of the +securities to be issued be subject to +voluntary escrow?**

No

Part 7E - Fees and expenses

---

**7E.1 Will there be a lead manager or broker to the proposed issue?**

Yes

**7E.1a Who is the lead manager/broker?**

The lead manager to the SPP is Bell Potter Securities Limited (Bell Potter).





**7E.1b What fee, commission or other consideration is payable to them for acting as lead manager/broker?**

In respect of the placement, Bell Potter will be paid in total a fee of 2% of the proceeds received by the Company under the placement (solely for lead managing the institutional placement).  
Bell Potter will also be reimbursed for customary expenses.

**7E.2 Is the proposed issue to be underwritten?**

No

**7E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed issue**

Fees and costs incurred by MVP in connection with the placement include share registry fees, settlement fees and legal fees.

Part 7F - Further Information

---

**7F.01 The purpose(s) for which the entity is issuing the securities**

To principally fund the acceleration of Pentrox EU's commercial expansion through operational investments in the EU and Australia and completion of clinical studies. Refer to slide 14 of the investor presentation released on 14 Dec 2020.

**7F.1 Will the entity be changing its dividend/distribution policy if the proposed issue proceeds?**

No

**7F.2 Any other information the entity wishes to provide about the proposed issue**

For further details of the placement please refer to the announcement released to ASX by the Company on Monday, 14 December 2020